Relay Therapeutics, Inc.

We are a clinical-stage, small molecule precision medicine company developing therapies for patients with cancer and genetic disease. Our Dynamo® platform integrates computational and experimental approaches to drug protein targets that have been difficult to address. Precision medicine aims to drug genetically validated target proteins, but some have been intractable with conventional drug discovery tools. Our approach shifts from a static view of protein targets to one based on protein motion, which we term Motion-Based Drug Design®. We apply these insights to drug discovery and design. We have used our technology platform to build a pipeline of product candidates for precision medicine targets where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients. We are advancing a pipeline of medicine candidates for precision oncology and genetic disease, including zovegalisib (RLY-2608). Zovegalisib (RLY-2608) is the first known allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor in clinical development. It is the lead program in our efforts to discover and develop mutant selective inhibitors of PI3Kα, targeting Breast Cancer and Solid Tumors in the ReDiscover Trial.